Gregory Daniel | Deputy Director
Duke University

Gregory Daniel, Deputy Director, Duke University

Dr. Gregory Daniel is a Clinical Professor in Duke's Fuqua School of Business and Deputy Director in the Duke-Robert J. Margolis Center for Health Policy at Duke University.  Dr. Daniel directs the DC-based office of the Center and leads the Center's pharmaceutical and medical device policy portfolio which includes developing policy and data strategies for improving development and access to innovative pharmaceutical and medical device technologies. This includes post-market evidence development to support increased value, improving regulatory science and drug development tools, optimizing biomedical innovation, and supporting drug and device payment reform. Dr. Daniel is also a Senior Advisor to the Reagan-Udall Foundation for the FDA and Adjunct Associate Professor in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy. Previously, he was Managing Director for Evidence Development & Biomedical Innovation in the Center for Health Policy and Fellow in Economic Studies at the Brookings Institution and Vice President, Government and Academic Research at HealthCore (subsidiary of Anthem, Inc).  Dr. Daniel’s research expertise includes utilizing electronic health data in designing research in health outcomes and pharmacoeconomics, comparative effectiveness, and drug safety and pharmacoepidemiology. Dr. Daniel received a PhD in pharmaceutical economics, policy and outcomes from the University of Arizona, as well as an MPH, MS, and BS in Pharmacy all from The Ohio State University.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 12:05

Developing new payment and alternative financing models to ensure higher value and better outcomes for the money spent in highly priced medical products

  • Adapting health system reimbursement models to encourage innovation in curative gene therapies and other innovative therapies 
  • Obstacles and opportunities for the increased implementation of value-based payment arrangements in the United States
  • Gene therapies vs. other highly priced treatments- looking into the sustainability of the healthcare system

back to speakers